Use of phosphorylated tau and p38gamma to treat a neurological condition

Research output: Patent

Abstract

The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acid residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b)introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject.

Original languageEnglish
Patent numberAU2017225907
IPCA61P 25/ 28 A I,A61K 38/17 (2006.01)
Priority date1/03/17
Filing date1/03/17
Publication statusPublished - 20 Sep 2018

Fingerprint Dive into the research topics of 'Use of phosphorylated tau and p38gamma to treat a neurological condition'. Together they form a unique fingerprint.

  • Cite this

    Ittner, L. M., & Ittner, A. A. (2018). IPC No. A61P 25/ 28 A I, A61K 38/17 (2006.01). Use of phosphorylated tau and p38gamma to treat a neurological condition. (Patent No. AU2017225907).